Paul Dorman

NanOlogy Sees ‘Encouraging Signs’ for Its Microparticle Drug Delivery in Nonoperable Lung Cancer Patients

by | Nov 20, 2022

Fort Worth-based NanOlogy has completed the enrollment of 18 patients in a Phase 2a trial for its proprietary particle drug delivery with standard-of care therapy in nonoperable lung cancer patients.

Lung cancer is the most lethal form of cancer with the highest mortality rate, according to the biotech, which aims to improve the treatment of cancer with its tumor-directed technology....

MORE
Protecting your privacy. We have strengthened our Privacy Policy to better protect you. This Policy includes our use of cookies to give you the best online experience and provide functionality essential to our services. By clicking ‘I Accept’ or by continuing to use our website, you are consenting to our Privacy Policy.